According to the clinical outcome of de novo SCLC and EGFR-TKI–induced transformed SCLC, we boldly speculate that the combination regimen of anlotinib with EC chemotherapy may be considered a potential therapeutic strategy. The gene discussed is EGFR; the disease is small cell lung carcinoma.